Remove 2025 Remove Biosimilars Remove Generic Medicine
article thumbnail

CHMP meeting highlights – May 2025

European Pharmaceutical Review

Generic medicine Emtricitabine/Tenofovir alafenamide Viatris (emtricitabine / tenofovir alafenamide), received a positive opinion to treat adults and adolescents with human immunodeficiency virus type 1 (HIV-1). The CHMP will issue its final recommendations of the medicine in due course.

article thumbnail

Waters, as a strategic partner to the pharma industry, can help India become a world leader in biosimilars

Express Pharma

For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?

article thumbnail

CHMP meeting highlights – January 2025

European Pharmaceutical Review

EMAs human medicines committee (CHMP) recommended eight medicines for EU marketing authorisation at its January 2025 meeting. Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy.